ArticleBlood2011
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02172365 (Retrospective Analysis of Treatment Outcomes of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia After TKI Failure), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retrospective Analysis of Treatment Outcomes of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia After TKI Failure
Who cites it
26 citing papers in PubMed, 78 citations in OpenAlex.
- Article
- The Impact of Pretransplant Use of Tyrosine Kinase Inhibitors on Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia - A Single-institution Retrospective Study.Internal medicine (Tokyo, Japan) · 2024Article
- Transplantation in CML in the TKI era: who, when, and how?Hematology. American Society of Hematology. Education Program · 2022Article
- Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT.Bone marrow transplantation · 2022Article
- CML Chapter.Cancer treatment and research · 2021Article
- [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.Journal of hematology & oncology · 2019Review
- Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.PharmacoEconomics · 2018Review
- Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Advanced drug delivery reviews · 2017Review
- All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand.Bone marrow transplantation · 2016Article
- [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Chronic myeloid leukemia: reminiscences and dreams.Haematologica · 2016Review
- Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.Current hematologic malignancy reports · 2016Review
- Allogeneic transplantation for CML in the TKI era: striking the right balance.Nature reviews. Clinical oncology · 2016Review
- Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm.Clinical lymphoma, myeloma & leukemia · 2015Review
- The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.Blood · 2015Review
- Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment.Biomarker insights · 2015Review
- Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Article
- An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.Bone marrow transplantation · 2014Review
- Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.Leukemia & lymphoma · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Hematopoietic stem cell transplantation (HSCT) is effective therapy for patients with chronic myelogenous leukemia (CML) but is now mostly indicated for patients who develop resistance to tyrosine kinase inhibitors (TKIs), which can be associated with point mutations in BCR-ABL1. We reviewed the outcomes of imatinib-resistant CML patients (chronic phase, n = 34; accelerated phase [AP], n = 9; and blast phase [BP], n = 4) who underwent HSCT and had BCR-ABL1 sequencing. Mutations were found in 19 patients (40%); 15 of 19 had advanced CML (AP + BP + second chronic phase). Patients with mutations were more likely to transform to AP/BP at time of imatinib failure (69% vs 35%, P = .03). Forty-two patients (89%) responded to HSCT: 32 (68%) had at least a major molecular response. The 2-year event-free survival was 36% and 58% (P = .05) for the mutant and nonmutant groups, respectively; and the 2-year overall survival was 44% and 76% (P = .02), respectively. HSCT is an important salvage option for TKI-resistant patients with or without BCR-ABL1 mutations. Patients with mutations were more likely to develop advanced disease and had worse outcomes after HSCT. HSCT should be considered early for patients deemed to have a low probability of responding to second-generation TKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.